Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design

Pancreatic Adenocarcinoma, Version 2.2012

(2017) Margaret A. Tempero et al.   Journal of the National Comprehensive Cancer Network

924 Venous Involvement During Pancreaticoduodenectomy: Is There a Need for Redefinition of “Borderline Resectable Disease”?

(2015) Kaitlyn J. Kelly et al.   GASTROENTEROLOGY

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

(2012) Peter J Hosein et al.   BMC CANCER

Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer

(2012) Francesco Leone et al.   CANCER

Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators

(2012) Matthew H. G. Katz et al.   CANCER

Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma

(2012) Jae-Lyun Lee et al.   SURGERY

Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy

(2011) Giuliano Barugola et al.   AMERICAN JOURNAL OF SURGERY

Arterial Resection During Pancreatectomy for Pancreatic Cancer

(2011) Nathan Mollberg et al.   ANNALS OF SURGERY

Correlation Between Radiographic Classification and Pathological Grade of Portal Vein Wall Invasion in Pancreatic Head Cancer

(2011) Akimasa Nakao et al.   ANNALS OF SURGERY

Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic Cancer

(2011) Jayme B. Stokes et al.   ANNALS OF SURGICAL ONCOLOGY

Failure to Adhere to Protocol Specified Radiation Therapy Guidelines Was Associated With Decreased Survival in RTOG 9704—A Phase III Trial of Adjuvant Chemotherapy and Chemoradiotherapy for Patients With Resected Adenocarcinoma of the Pancreas

(2011) Ross A. Abrams et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Potential Contribution of Preoperative Neoadjuvant Concurrent Chemoradiation Therapy on Margin-Negative Resection in Borderline Resectable Pancreatic Cancer

(2011) Chang Moo Kang et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer

(2011) Matthew H. G. Katz et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment

(2011) Shinichiro Takahashi et al.   Journal of Hepato-Biliary-Pancreatic Sciences

NeoGemTax: Gemcitabine and Docetaxel as Neoadjuvant Treatment for Locally Advanced Nonmetastasized Pancreatic Cancer

(2011) Klaus Sahora et al.   WORLD JOURNAL OF SURGERY

Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial

(2010) Matthew H. G. Katz et al.   ANNALS OF SURGICAL ONCOLOGY

Borderline Resectable Pancreatic Cancer: What Have We Learned and Where Do We Go From Here?

(2010) Matthew H. G. Katz et al.   ANNALS OF SURGICAL ONCOLOGY

Defining Venous Involvement in Borderline Resectable Pancreatic Cancer

(2010) Yun Shin Chun et al.   ANNALS OF SURGICAL ONCOLOGY

Pancreatic Cancer Tumor Size on CT Scan Versus Pathologic Specimen: Implications for Radiation Treatment Planning

(2010) Nils D. Arvold et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma

(2010) Jerome Landry et al.   JOURNAL OF SURGICAL ONCOLOGY

NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer

(2010) Klaus Sahora et al.   SURGERY

Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer

(2010) Rebecca J. McClaine et al.   HPB

Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages

(2010) Sonja Gillen et al.   PLOS MEDICINE

Variability in Reporting Resection Margin Status in Pancreatic Cancer

(2009) Caroline S. Verbeke et al.   ANNALS OF SURGERY

A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer

(2009) Alessio G. Morganti et al.   ANNALS OF SURGICAL ONCOLOGY

Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement

(2009) Ross A. Abrams et al.   ANNALS OF SURGICAL ONCOLOGY

Surgical Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement

(2009) Douglas B. Evans et al.   ANNALS OF SURGICAL ONCOLOGY

Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

(2009) Mark P. Callery et al.   ANNALS OF SURGICAL ONCOLOGY

Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma

(2009) O. Turrini et al.   EJSO

Surgical Results After Preoperative Chemoradiation Therapy for Patients With Pancreatic Cancer

(2009) Sohei Satoi et al.   PANCREAS

Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma

(2008) Kimberly M. Brown et al.   AMERICAN JOURNAL OF SURGERY

Survival After Pancreatectomy With Major Arterial Resection and Reconstruction

(2008) Karyn B. Stitzenberg et al.   ANNALS OF SURGICAL ONCOLOGY

Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial

(2008) William Small et al.   JOURNAL OF CLINICAL ONCOLOGY